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Abstract  Bacillus  anthracis  protective  antigen  (PA)  is  a  well  known  and  relevant  immunogenic
protein that  is  the  basis  for  both  anthrax  vaccines  and  diagnostic  methods.  Properly  folded
antigenic  PA  is  necessary  for  these  applications.  In  this  study  a  high  level  of  PA  was  obtained  in
recombinant  Escherichia  coli. The  protein  was  initially  accumulated  in  inclusion  bodies,  which
facilitated  its  efﬁcient  puriﬁcation  by  simple  washing  steps;  however,  it  could  not  be  recognized
by speciﬁc  antibodies.  Refolding  conditions  were  subsequently  analyzed  in  a  high-throughput
manner  that  enabled  nearly  a  hundred  different  conditions  to  be  tested  simultaneously.  The
recovery  of  the  ability  of  PA  to  be  recognized  by  antibodies  was  screened  by  dot  blot  using
a coefﬁcient  that  provided  a  measure  of  properly  refolded  protein  levels  with  a  high  degree
of discrimination.  The  best  refolding  conditions  resulted  in  a  tenfold  increase  in  the  intensity
of the  dot  blot  compared  to  the  control.  The  only  refolding  additive  that  consistently  yielded
good results  was  L-arginine.  The  statistical  analysis  identiﬁed  both  cooperative  and  negative
interactions  between  the  different  refolding  additives.  The  high-throughput  approach  described
in this  study  that  enabled  overproduction,  puriﬁcation  and  refolding  of  PA  in  a  simple  and
straightforward  manner,  can  be  potentially  useful  for  the  rapid  screening  of  adequate  refolding
conditions  for  other  overexpressed  antigenic  proteins.
© 2015  Asociación  Argentina  de  Microbiología.  Published  by  Elsevier  España,  S.L.U.  This  is
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Expresión  y  renaturalización  del  antígeno  protector  de  Bacillus  anthracis: un  modelo
para  evaluar  el  replegado  de  proteínas  antigénicas  recombinantes  a  gran  escala
Resumen  El  antígeno  protector  de  Bacillus  anthracis  (protective  antigen,  PA)  es  una  impor-
tante proteína  inmunogénica,  en  la  que  se  basan  tanto  las  vacunas  contra  el  ántrax/carbunclo
como varios  métodos  diagnósticos.  Para  estas  aplicaciones  es  esencial  que  el  PA  mantenga  sus
propiedades  antigénicas,  para  lo  cual  debe  estar  correctamente  plegado.  En  este  estudio  se
obtuvieron  altos  niveles  del  PA  en  Escherichia  coli  recombinante.  Inicialmente,  la  proteína  se
acumuló desnaturalizada  en  cuerpos  de  inclusión,  lo  que  facilitó  su  eﬁciente  puriﬁcación  en
simples pasos  de  lavado,  pero  no  fue  reconocida  por  anticuerpos  especíﬁcos.  Se  analizaron  las
condiciones  de  replegado  con  un  sistema  de  alto  rendimiento,  evaluando  simultáneamente  casi
un centenar  de  condiciones  diferentes.  La  recuperación  de  la  capacidad  del  PA  de  ser  recono-
cido por  los  anticuerpos  se  evaluó  por  dot  blot  utilizando  un  coeﬁciente  que  proporcionó  una
medida de  los  niveles  de  proteína  correctamente  plegada,  con  un  alto  grado  de  discriminación.
Las mejores  condiciones  de  renaturalización  permitieron  un  aumento  de  diez  veces  en  la  inten-
sidad de  los  dot  blots  con  respecto  del  control.  El  único  aditivo  que  produjo  buenos  resultados  de
forma constante  fue  la  l-arginina.  El  análisis  estadístico  de  las  interacciones  entre  los  diferentes
aditivos de  replegado  permitió  identiﬁcar  tanto  interacciones  cooperativas  como  negativas.  El
enfoque  de  alto  rendimiento  descripto  en  este  trabajo,  que  permitió  la  sobreproducción,  puriﬁ-
cación y  plegado  del  PA  de  una  manera  sencilla  y  directa,  puede  ser  potencialmente  útil  para
el rápido  screening  de  las  condiciones  adecuadas  de  replegado  cuando  se  sobreexpresan  otras
proteínas  antigénicas.
©  2015  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,  S.L.U.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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ntroduction
rom  ancient  times  (ﬁfth  Biblical  plague)  to  the  present
ay  (bioterrorism),  Bacillus  anthracis  continues  to  be  a
pecially  relevant  human  and  veterinary  pathogen27,30.  Its
rotective  antigen  (PA)  is  the  basis  for  different  anthrax
accines,  including  second  generation  recombinant  PA  and
hird  generation  modiﬁed  rPA  vaccines3,7,10,23,31. This  anti-
en  is  also  essential  for  the  evaluation  of  the  serological
tatus  of  vaccinated  humans  and  animals6,17,21,25.  Examples
f  these  applications  are  diverse,  and  can  range  from  ﬁeld
erodiagnosis  of  human  cutaneous  anthrax14 to  serological
valuation  of  wild  animals16,35.
PA  is  a  protein  of  83  kDa  organized  in  four  functional
omains27,  for  a  long  time  was  puriﬁed  from  B.  anthracis
ulture  supernatants15,28.  In  an  effort  to  increase  its  yield,
hile  avoiding  the  inconvenience  of  working  with  this
athogen,  PA  was  produced  in  Escherichia  coli  expressing
agA,  the  gene  responsible  for  PA  synthesis  in  B.  anthracis.
he  ﬁrst  studies  that  attempted  to  obtain  this  protein
rom  recombinant  E.  coli  reported  that  it  suffered  exten-
ive  degradation  during  the  puriﬁcation  process,  and  also
hat  the  presence  of  large  amounts  of  contaminant  proteins
ade  time-consuming  procedures  necessary32.  Later,  full-
ength  PA  was  expressed  in  E.  coli  as  a  polyhistidine-tagged
usion  protein,  yielding  insoluble  protein  aggregates18.
ore  recently,  untagged  PA  obtained  as  inclusion  bodies
insoluble  aggregates  of  misfolded  proteins)  was  puriﬁed
y  hydrophobic-interaction  chromatography  yielding  active
A22.  Biologically  active  PA  was  also  produced  in  the
eriplasm  of  recombinant  E.  coli1,19,20.
Nowadays,  the  expression  of  recombinant  proteins
s  essential  for  many  biotechnological  applications  that
B
cenerally  require  that  these  proteins  conserve  their  native
olding  characteristics  to  remain  functionally  active.  When
igh  expression  vectors  are  used  for  the  overexpression  of
ntracellular  proteins,  these  are  usually  accumulated  as
nclusion  bodies  that  lack  biological  activity.  Expression  as
nclusion  bodies  facilitates  protein  puriﬁcation,  as  they  can
e  easily  separated  from  cell  debris13.  However,  hurdles
rise  when  renaturation  is  attempted  in  order  to  obtain
 properly  refolded  active  protein34. Multiple  refolding
onditions  have  to  be  assayed  because  there  is  not  a
niversally  applicable  protocol:  speciﬁc  conditions  must  be
et  for  each  protein  and  these  cannot  be  determined  a
riori.  As  a  result,  ﬁnding  the  conditions  for  the  efﬁcient
efolding  of  recombinant  proteins  can  be  a  laborious  task.
On  the  other  hand,  when  expressed  as  inclusion  bodies,
ome  antigenic  proteins  can  still  be  recognized  by  spe-
iﬁc  antibodies  in  the  denatured  state.  Others  need  to  be
efolded,  and  in  these  cases  antibody  recognition  can  be
seful  to  monitor  the  efﬁcacy  of  the  refolding  protocol  used.
In  this  work,  a  high  throughput  approach  was  used  to
fﬁciently  monitor  the  correct  refolding  of  recombinant
A,  initially  obtained  as  inclusion  bodies.  The  recovery  of
he  capability  of  PA  to  be  recognized  by  antibodies  was
uantiﬁed  allowing  the  assessment  and  detailed  analysis  of
ultiple  different  refolding  conditions.
aterials and methods.  anthracis  reference  strain  Sterne  34F2 used  in  this  study
arries  the  virulence  plasmid  pXO1  and  lacks  pXO2.  It  had
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eHigh-throughput  screening  of  protective  antigen  refolding  
been  previously  typiﬁed  using  the  vrrA  locus,  as  belong-
ing  to  the  VNTR4 variant26.  Boiled  crude  lysates  were  used
as  templates  for  PCR  (polymerase  chain  reaction):  several
colonies  grown  overnight  at  37 ◦C  in  Tryptic  Soy  Agar  (Difco)
were  resuspended  in  Tris-EDTA  buffer  (10  mM  Tris--HCl,  1  mM
EDTA)  and  boiled  at  98 ◦C  during  10  min,  centrifuged  at
14,000  ×  g  for  30  s  and  the  supernatant  directly  used  as
DNA  template  for  pagA  ampliﬁcation.  DNA  puriﬁcation  steps
were  avoided  to  reduce  microorganism  manipulation  to  a
minimum.  It  was  important  to  use  a  fresh  non-sporulated
culture  as  a  DNA  source  for  PCR.  The  PCR  mixture  con-
tained  1×  AccuPrime  Pfx  Reaction  Mix,  1  mM  MgCl2,  1.5  U
of  AccuPrime  Pfx  DNA  polimerase  (Invitrogen),  1  M  each
primer  (pagA-forward  and  pagA-reverse)  and  5  l  of  DNA
template  in  a  total  volume  of  50  l.  The  oligonucleotides
pagA-forward  (5′-CACCTTATTAAATGAATCWGAATCAAGTTCC-
3′)  and  pagA-reverse  (5′-TTATCCTATCTCATAGCCTTTTTTAGA-
3′)  were  designed  using  the  Oligo  program29,  with  manual
optimization.  The  template  was  replaced  by  nuclease-free
water  for  the  negative  PCR  control.  PCR  assay  was  car-
ried  out  as  follows:  95 ◦C  for  5  min,  followed  by  35  cycles
of  denaturation  at  95 ◦C  for  45  s,  annealing  at  55 ◦C  for
45  s  and  extension  at  68 ◦C  for  3  min,  with  a  ﬁnal  cycle
at  68 ◦C  during  20  min.  Following  the  PCR,  10  l  of  ampli-
ﬁed  product  were  puriﬁed  using  the  Wizard  SV  gel  and  PCR
clean-up  System  kit  (Promega).  Gateway  pENTR/D-TOPO
(Invitrogen)  was  used  as  an  entry  vector  for  cloning  pagA
and  transformed  into  competent  E.  coli  One  Shot  TOP10
(Invitrogen),  according  to  the  manufacturer’s  instructions.
Expression  plasmids,  pEXP17-pagA,  were  generated  by  site-
speciﬁc  recombination,  using  LR  clonase  II,  between  the
pENTR/D-TOPO-pagA  plasmid  previously  obtained  and  the
destination  vector  pDEST17,  using  the  E.  coli  Expression
System  kit  from  the  Gateway  Technology  (Invitrogen),  with
subsequent  transformation  of  competent  E.  coli  One  Shot
TOP10  (Invitrogen).  The  expression  plasmids  were  used  to
transform  competent  E.  coli  BL21  Star  (DE3)  pLysS  One  Shot
(Invitrogen)  to  obtain  expression  clones.  Plasmids  from  two
different  expression  clones  were  veriﬁed  by  sequencing.
Theoretical  molecular  weight  and  protein  isoelectric
point  (pI)  of  the  fusion  recombinant  protein  PA  were  com-
puted  using  ProtParam  on  the  ExPASy  Server12.
Expression,  puriﬁcation  and  refolding  of  PA
PA  was  expressed  by  culturing  expression  clones  in  200  ml
MagicMedia  E.  coli  Expression  Medium  (Invitrogen),  in  the
presence  of  ampicillin  (100  g/ml)  and  chloramphenicol
(34  g/ml),  in  shake  ﬂasks  (250  r.p.m.)  at  37 ◦C  during
24  h  (OD595 =  2.1).  To  analyze  inclusion  bodies  versus  sol-
uble  fraction  proteins,  bacteria  were  centrifuged  during
2  min  at  16,000  ×  g  resuspended  in  BugBuster  Protein  Extrac-
tion  Reagent  (Novagen)  and  Benzonase  Nuclease  (Novagen),
and  incubated  at  room  temperature  for  an  hour  with  gen-
tle  agitation,  according  to  the  manufacturer’s  instructions.
Inclusion  bodies  were  separated  from  soluble  proteins  by
centrifugation  at  5200  ×  g  for  5  min.  Analysis  of  total,  solu-
ble  and  insoluble  proteins  was  performed  in  15  %  SDS-PAGE,
followed  by  Coomassie  Brilliant  G-250  staining.
To  purify  inclusion  bodies,  cells  were  collected  and
frozen  at  −20 ◦C  until  processed.  One  gram  of  bacteria
o
d
l
i7
as  suspended  in  5  ml  of  BugBuster  Protein  Extraction
eagent  and  125  U  of  Benzonase  Nuclease.  Previous  to
efolding,  inclusion  bodies  were  solubilized  overnight  at
oom  temperature  in  50  mM  Tris--HCl,  200  mM  NaCl,  2  mM
DTA,  10  mM  tris  (2-carboxyethyl)  phosphine  (TCEP),  7  M
uanidine  pH  8.0,  with  shaking  at  250  r.p.m.  Insoluble
ebris  was  removed  by  centrifugation  at  16  000  ×  g  for
5  min  at  4 ◦C,  and  PA  purity  was  checked  by  SDS-PAGE.
Protein  concentration  was  measured  by  the  Bradford
ethod4 in  a  microplate  format.  Samples  (25  l)  were
iluted  in  155  l water,  and  45  l  reagent  concentrate  of
he  Bio-Rad  Protein  Assay  (Bio-Rad)  were  added.
The  iFOLD  Protein  Refolding  System  2  (Novagen)  was
sed  to  simultaneously  assess  multiple  refolding  condi-
ions  in  a  96-well  plate:  10  l of  denatured  protein  were
dded  to  each  well  containing  0.5  ml  of  refolding  buffer,
btaining  a  ﬁnal  concentration  of  100  ng/l of  PA.  A  multi-
hannel  pipettor  was  used  to  rapidly  mix  each  well  by
ipetting  up  and  down  ten  times.  The  refolding  buffers
ere:  MOPS  pH  7.0,  HEPES  pH  7.5,  EPPS  pH  8.0,  TAPS  pH
.5  or  CHES  pH  9.0,  50  mM  each,  with  diverse  combina-
ions  of  salts,  redox  agents  or  refolding  additives:  NaCl:KCl
24:1  mM  or  240:1  mM);  TCEP  1  mM;  reduced:  oxidized  glu-
athione  (9:1  mM  or  6:4  mM);  EDTA  1  mM;  l-arginine  0.5  M;
EG3350  0.06  %  w/v;  non-detergent  sulfobetaines  NDSB-201
r  NDSB-256  0.5  M  or  1  M  each;  trehalose  0.58  M;  sorbitol
.5  M;  methyl--d-cyclodextrin  10  mM;  CaCl2, MgCl2,  MnCl2,
nd  ZnCl2: 0.25  mM  each  one.  Incubation  was  carried  out  at
oom  temperature  for  16  h,  with  gentle  agitation.  After  that,
t  was  left  to  stand  for  1  h  and  the  soluble  protein  refolding
evel  was  monitored  by  dot  blotting.  Soluble  protein  was
uantiﬁed  by  Bradford.
ssessment  of  PA  refolding  and  antibody
ecognition
ntibody  recognition  of  PA  was  assayed  by  Western  or  dot
lots  using  nitrocellulose  membranes  (Pall  Biodyne).  For  dot
lots,  2  l of  the  protein  solutions  were  directly  spotted  onto
he  membranes.  Membranes  were  blocked  with  5  %  nonfat
ilk  in  TS  buffer  (50  mM  Tris--HCl  pH  7.5,  150  mM  NaCl)  and
ncubated  for  45  min  with  1:200  dilution  of  a  mix  of  goat  anti-
-terminal  and  anti-internal  PA  region  polyclonal  antibodies,
A  (bc-19)  and  PA  (bE-16)  respectively  (Santa  Cruz  Biotech-
ology,  Inc.).  Afterwards,  membranes  were  incubated  with
 1:2000  dilution  of  donkey  anti-goat  IgG  horseradish  perox-
dase  conjugate  (Santa  Cruz  Biotechnology,  Inc.).
uantiﬁcation  and  computational  analysis  of  dot
lots
ot  blots  were  used  to  assess  multiple  refolding  conditions
t  the  same  time.  To  avoid  uncertainties  due  to  the  irregular
ispersion  of  each  droplet  onto  the  nitrocellulose  mem-
rane,  a  method  to  quantify  dot  blot  results  was  used.  This
ethod  was  based  on  an  image  processing  technique  that
xtracted,  from  an  image  of  the  multiwell  plate,  a  matrix
f  numerical  coefﬁcients  that  was  used  to  sort  reagent  refol-
ing  capabilities.  An  index  standing  for  the  image  intensity
evel  of  each  dot  and  its  respective  area  was  deﬁned.  This
ndex,  henceforth  called  coefﬁcient  D,  was  automatically
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omputed  using  the  tools  available  in  Matlab  (Mathworks,
atick,  USA).  First,  a  grayscale,  high  resolution  digital  image
f  the  whole  plate  layout  was  recorded.  Then,  a  contour
etection  algorithm  automatically  recognized  the  edge  of
ach  individual  dot,  distinguishing  it  from  the  plate  back-
round,  and  computed  the  dot  area  (A)  deﬁned  by  the  pixels
nside  the  previously  found  edge.  For  each  separate  well,
 relative  density  value  (  density)  was  computed  by  sub-
racting  the  mean  density  value  of  the  dot  from  the  mean
ensity  of  the  image  background.  Finally,  D  was  computed
or  each  dot  by  multiplying  its  relative  density  by  the  respec-
ive  area  (D  =    density  ×  A).  Coefﬁcient  D  was  used  as  an
ndex  of  antibody  recognition,  reﬂecting  proper  refolding  of
A.
In  order  to  evaluate  the  refolding  capability  of  the  dif-
erent  buffers  and  additives  studied,  statistical  methods
ere  used  to  evaluate  results  variability.  An  exploratory
ata  Analysis  of  Variance  (Kruskal--Wallis  non-parametric
ne-way  ANOVA,  Matlab  Statistical  Toolbox)  was  ﬁrst  per-
ormed  to  identify  those  factors  leading  to  higher  coefﬁcient
 values.  As  in  the  multiwell  plate  assay,  different  factors
ere  simultaneously  considered,  two-way  ANOVA  was  used
o  search  for  possible  interactions  between  them.  In  both
nalyses,  results  were  considered  statistically  signiﬁcant  if
he  signiﬁcance  level  (p)  was  less  than  0.05.
esults and discussion
xpression  and  puriﬁcation  of  recombinant  PA
he  N-terminal  His-tagged  fusion  PA  (84.98  kDa)  constructed
n  this  work  has  756  aminoacids,  no  cysteines  and  a theoret-
cal  pI  of  5.97.  Expression  of  high  levels  of  this  recombinant
rotein  (200  g  per  ml  of  bacterial  culture)  was  achieved
n  an  expression  medium  that  does  not  require  induction.
hen  the  crude  extract  was  analyzed  by  SDS-PAGE,  a
ominant  protein  band  of  the  expected  size  was  observed
Fig.  1a,  lanes  1  and  2).  Analysis  of  the  soluble  and  insoluble
ractions  demonstrated  that  PA  appeared  exclusively  in  the
nsoluble  fraction  (Fig.  1a,  lanes  3  and  4),  and  that  most  of
a bkDa kDa
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igure  1  (a)  SDS-PAGE  of  recombinant  PA  (indicated  by  the
rrow)  expressed  in  E.  coli  BL21  Star  (DE3)  pLysS  carrying  plas-
id pEXP17-pagA.  Lanes  1  and  2:  total  protein,  lanes  3  and
: insoluble  fraction,  lanes  5  and  6:  soluble  fraction.  Results
re shown  for  two  different  clones,  corresponding  to  odd  and
ven lanes  respectively.  (b)  SDS-PAGE  of  washed  inclusion  bodies
olubilized  in  6  M  guanidine.
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he  contaminant  proteins  remained  in  the  supernatant  as
oluble  proteins  during  cellular  lysis  (Fig.  1a,  lanes  5  and
).  The  T7  lysozyme  produced  by  the  host  strain,  combined
ith  a  special  reagent  that  causes  the  gentle  disruption  of
he  cell  wall,  facilitated  bacterial  lysis  permitting  a  rapid
nd  easy  recovery  of  inclusion  bodies,  which  after  several
ashes  formed  a  distinct  white  pellet.  Analysis  of  the
uanidine  solubilized  pellet  by  SDS-PAGE  (Fig.  1b)  revealed
 remarkable  high  purity,  considering  that  no  puriﬁcation
teps  other  than  simple  washes  were  performed.  Anti-C-
erminus  or  anti-internal  PA  region  polyclonal  antibodies
id  not  recognize  the  recombinant  protein  in  Western  blots
data  not  shown),  indicating  that  PA  did  not  retain  the
apability  to  be  recognized  by  speciﬁc  antibodies  in  this
tage.
Previous  studies  reporting  the  production  of  recombi-
ant  PA  in  E.  coli  involved  multiple  puriﬁcation  steps.
n  some  studies  in  which  PA  was  obtained  as  inclusion
odies,  it  was  subjected  to  several  puriﬁcation  steps  includ-
ng  metal  chelate  afﬁnity  chromatography18,  or  ammonium
ulfate  precipitations  followed  by  hydrophobic-interaction
hromatography22. Other  researchers  obtained  PA  in  the
eriplasm,  and  used  several  different  chromatographic  steps
o  partially  purify  PA,  such  as  ion  exchange  and  hydropho-
ic  interaction  chromatography1, or  ion  exchange  and
ydroxyapatite  chromatography20.  The  high  expression  of
A  obtained  in  the  present  work,  combined  with  the  low
ackground  and  the  enrichment  of  PA  in  the  lysis  step,  facil-
tated  PA  puriﬁcation  using  only  washes,  without  the  need
or  chromatographic  puriﬁcation  steps.
ssessment  of  PA  renaturing  conditions
s  PA  was  obtained  in  inclusion  bodies,  we  assumed  that
ts  lack  of  antibody  recognition  was  due  to  improper  fold-
ng.  Multiple  renaturing  conditions  were  subsequently  tested
or  guanidine  solubilized  inclusion  bodies  using  a  refol-
ing  system  that  provides  nearly  a  hundred  unique  buffers,
llowing  a  high-throughput  refolding  screening.  This  sys-
em  consists  of  a 96-well  plate,  each  containing  a  different
efolding  solution.  The  renaturing  conditions  are  generated
hrough  different  buffers  with  the  addition  of  diverse  con-
entrations  and  combinations  of  the  following  components:
aCl  and  KCl,  to  supply  different  ionic  forces;  TCEP  and/or
educed-oxidized  glutathione  as  redox  agents;  l-arginine,
EG,  non-detergent  sulfobetaines  NDSB-201  and  NDSB-256,
DTA,  trehalose,  sorbitol,  -cyclodextrin  and  several  cations
s  renaturing  additives.  We  expected  that  dilution  of  PA  in
ome  of  the  multiple  refolding  solutions  would  lead  to  the
orrect  refolding,  restoring  its  ability  to  be  recognized  by
ntibodies.
As  the  properly  refolded  PA  should  remain  in  the  sol-
ble  state,  renaturing  was  monitored  both  by  assaying
he  concentration  (Bradford)  and  antibody  binding  (dot
lots)  of  the  protein  that  stayed  soluble  in  each  well
Table  1  and  Fig.  2).  The  data  presented  in  this  work
esult  from  a  single  replicate  testing  96  different  buffers
nd  additives  conveniently  contained  in  a  single  refolding
late.  Protein  quantiﬁcation  was  useful  to  estimate  soluble
rotein  in  most  conditions  assayed,  however,  some  buffer
omponents  interfered  with  the  Bradford  method.  For
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Table  1  Assessment  of  all  refolding  conditions
No.a Well  Coefﬁcient
D
Bradfordb Buffer  pH  Redox  agentsc Additivesd NDSBe Saltsf Metals/
EDTAg
1  C4  1178  0.69  HEPES  7.5  GSH  +  GSSG(1) --  NDSB-256(2) +  EDTA
2 F12  1172  0.63  CHES  9  TCEP  --  NDSB-256(2) +  --
3 C10  1143  0.71  TAPS  8.5  GSH  +  GSSG(2) --  NDSB-256(2) +  EDTA
4 F6  1139  0.72  EPPS  8  --  --  NDSB-256(2) −  --
5 G9  1128  0.80  TAPS  8.5  --  --  NDSB-256(1) +  --
6 B7  1102  0.68  EPPS  8  GSH  +  GSSG(2) --  NDSB-256(2) +  --
7 D6  1087  0.72  EPPS  8  GSH  +  GSSG(1) --  NDSB-256(1) −  EDTA
8 D10  1085  0.75  TAPS  8.5  GSH  +  GSSG(2) --  NDSB-256(1) +  --
9 G6  1081  0.67 EPPS  8  --  PEG3350  --  +  --
10 H8  1047  0.71 TAPS 8.5 -- --  NDSB-201(1) +  --
11 D9  1044  0.82  TAPS  8.5  GSH  +  GSSG(1) l-arginine  --  +  EDTA
12 D4  995  0.72  HEPES  7.5  GSH  +  GSSG(1) --  NDSB-256(2) −  --
13 F4  991  0.74  HEPES  7.5  --  --  NDSB-201(2) +  --
14 C9  987  0.80  TAPS  8.5  GSH  +  GSSG(1) --  NDSB-201(2) +  --
15 A7  980  0.70  EPPS  8  GSH  +  GSSG(2) --  NDSB-201(1) −  EDTA
16 B9  969  0.75  TAPS  8.5  GSH  +  GSSG(1) --  NDSB-201(2) −  EDTA
17 A2  961  0.75  MOPS  7  GSH  +  GSSG(2) l-arginine  --  +  EDTA
18 G11  951  0.75  CHES  9  TCEP  --  NDSB-201(2) +  --
19 C5  944  0.70  HEPES  7.5  GSH  +  GSSG(2) --  NDSB-256(1) −  EDTA
20 E11  941  0.78  CHES  9  --  --  NDSB-256(1) −  --
21 E5  934  0.85  HEPES  7.5  --  l-arginine  --  −  --
22 B4  933  0.66  HEPES  7.5  GSH  +  GSSG(1) --  NDSB-201(1) +  --
23 C3  887  0.69  MOPS  7  TCEP  --  NDSB-256(2) +  Metals
24 E8  879  0.79  TAPS  8.5  TCEP  Sorbitol  --  +  --
25 B10  877  1.00  TAPS  8.5  GSH  +  GSSG(2) PEG3350  --  +  EDTA
26 G8  877  0.66  TAPS  8.5  TCEP  PEG3350  --  −  --
27 G10  875  0.61  CHES  9  --  Trehalose  --  +  Metals
28 E4  874  0.86  HEPES  7.5  GSH  +  GSSG(1) l-arginine  --  +  --
29 D7  872  0.65  EPPS  8  GSH  +  GSSG(2) --  NDSB-201(2) +  EDTA
30 A10  866  0.75  TAPS  8.5  GSH  +  GSSG(2) sorbitol  --  +  --
31 A6  850  0.71  EPPS  8  GSH  +  GSSG(1) --  NDSB-256(1) −  --
32 G7  849  0.78  EPPS  8  TCEP  l-arginine  --  +  --
33 E7  836  0.60  EPPS  8  GSH  +  GSSG(2) Trehalose  --  +  --
34 F11  835  0.62  CHES  9  TCEP  --  NDSB-201(1) +  Metals
35 D5  833  0.58  HEPES  7.5  GSH  +  GSSG(2) PEG3350  --  −  --
36 C8  819  0.85 TAPS  8.5  TCEP  l-arginine  --  +  Metals
37 H9  803  0.69  TAPS  8.5  --  --  --  −  --
38 B1  798  0.79  MOPS  7  GSH  +  GSSG(1) l-arginine  --  +  --
39 F10  777  0.59  CHES  9  --  Sorbitol  --  +  --
40 D8  768  0.62  TAPS  8.5  TCEP  Trehalose  --  −  --
41 H4  765  1.32  HEPES  7.5  --  -Cyclodextrin  --  −  --
42 B11  761  0.60  CHES  9  GSH  +  GSSG(1) --  NDSB-256(2) +  EDTA
43 E10  760  0.76  TAPS  8.5  GSH  +  GSSG(2) --  NDSB-201(1) −  --
44 B12  759  0.60  CHES  9  GSH  +  GSSG(2) l-arginine  --  +  EDTA
45 G2  759  0.66  MOPS  7  --  --  --  +  --
46 E6  753  0.66  EPPS  8  GSH  +  GSSG(1) PEG3350  --  +  --
47 A8  751  1.26  EPPS  8  TCEP  -Cyclodextrin  --  +  --
48 C1  744  0.52  MOPS  7  GSH  +  GSSG(1) PEG3350  --  −  EDTA
49 G12  732  0.79  CHES  9  TCEP  l-arginine  --  −  Metals
50 D3  732  0.95  HEPES  7.5  TCEP  Sorbitol  --  +  --
51 A4  721  0.61  HEPES  7.5  GSH  +  GSSG(1) Trehalose  --  +  EDTA
52 F3  705  1.35  HEPES  7.5  TCEP  -Cyclodextrin  --  −  --
53 H5  705  0.60  EPPS  8  --  --  --  −  --
54 F5  703  0.55  HEPES  7.5  --  --  --  −  --
55 B2  702  0.56  MOPS  7  GSH  +  GSSG(2) --  NDSB-256(1) +  EDTA
56 G5  692  0.51  EPPS  8  --  --  NDSB-201(2) +  Metals
57 A9  674  0.67  TAPS  8.5  GSH  +  GSSG(1) --  --  −  --
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Table  1  (Continued)
No.a Well  Coefﬁcient
D
Bradfordb Buffer  pH  Redox  agentsc Additivesd NDSBe Saltsf Metals/
EDTAg
58  B5  670  0.60  HEPES  7.5  GSH  +  GSSG(2) --  --  −  EDTA
59 C6  663  1.30  EPPS  8  GSH  +  GSSG(1) -Cyclodextrin  --  +  --
60 C7  646  0.59  EPPS  8  GSH  +  GSSG(2) Trehalose  --  −  EDTA
61 A5  607  0.62  HEPES  7.5  GSH  +  GSSG(2) --  --  +  --
62 H12  599  0.65  CHES  9  TCEP  PEG3350  --  −  Metals
63 H1  581  0.54 MOPS  7  --  --  --  −  --
64 F7  577  0.61 EPPS  8  TCEP  Sorbitol  --  +  Metals
65 G1  568  0.59  MOPS  7  --  Trehalose  --  +  --
66 A1  544  1.26  MOPS  7  GSH  +  GSSG(1) -Cyclodextrin  --  +  EDTA
67 H11  535  0.59  CHES  9  TCEP  --  --  +  --
68 E1  503  0.55  MOPS  7  GSH  +  GSSG(1) Trehalose  --  −  --
69 H10  489  0.59  CHES  9  --  --  --  −  --
70 D1  485  0.51  MOPS  7  GSH  +  GSSG(1) --  --  +  EDTA
71 B6  481  0.51  EPPS  8  GSH  +  GSSG(1) Sorbitol  --  −  EDTA
72 B3  469  0.44  MOPS  7  TCEP  --  NDSB-201(2) −  Metals
73 F9  467  0.46  TAPS  8.5  --  Trehalose  --  +  Metals
74 A3  465  0.46  MOPS  7  TCEP  --  NDSB-256(1) +  Metals
75 F2  463  0.70  MOPS  7  --  --  NDSB-256(2) +  Metals
76 E2  453  0.56  MOPS  7  GSH  +  GSSG(2) --  NDSB-201(2) −  --
77 E3  449  0.48  HEPES  7.5  TCEP  --  NDSB-201(1) +  Metals
78 E9  423  1.31  TAPS  8.5  --  -Cyclodextrin  --  +  Metals
79 H2  410  0.42  MOPS  7  --  --  NDSB-201(1) +  Metals
80 D2  328  0.48  MOPS  7  GSH  +  GSSG(2) --  NDSB-201(1) −  --
81 A12  308  0.41  CHES  9  GSH  +  GSSG(2) Sorbitol  --  +  EDTA
82 G3  303  0.42  HEPES  7.5  TCEP  Trehalose  --  +  Metals
83 G4  293  0.45  HEPES  7.5  --  --  NDSB-201(2) +  Metals
84 F1  252  0.43  MOPS  7  --  Sorbitol  --  −  Metals
85 H3  226  0.38  HEPES  7.5  --  PEG3350  --  +  Metals
86 C12  212  0.41  CHES  9  GSH  +  GSSG(2) -Cyclodextrin  --  +  --
87 E12  208  0.79  CHES  9  GSH  +  GSSG(2) PEG3350  --  +  --
88 D11  195  0.44  CHES  9  GSH  +  GSSG(1) --  NDSB-256(1) +  --
89 C2  189  1.08  MOPS  7  GSH  +  GSSG(2) -Cyclodextrin  --  +  EDTA
90 H6  184  0.39  EPPS  8  --  --  --  +  Metals
91 F8  160  1.31  TAPS  8.5  TCEP  -Cyclodextrin  --  --  Metals
92 D12  136  0.46  CHES  9  GSH  +  GSSG(2) -Cyclodextrin  --  +  --
93 B8  123  0.40  EPPS  8  TCEP  --  --  +  Metals
94 H7  119  0.40  H2O  7  --  --  --  --  --
95 A11  32  0.47  CHES  9  GSH  +  GSSG(1) Sorbitol  --  +  --
96 C11  13  0.41  CHES  9  GSH  +  GSSG(1) --  NDSB-201(1) +  EDTA
a Order by decreasing coefﬁcient D values.
b Absorbance values at 595 nm.
c Redox agents: reduced and oxidized glutathione (GSH + GSSG) 9:1 mM(1) or 6:4 mM(2); TCEP 1 mM.
d Additives: l-arginine 0.5 M; PEG3350 0.06 % w/v; trehalose 0.58 M; sorbitol 1.5 M; methyl--d-cyclodextrin 10 mM.
e NDSB: NDSB-201(1) 0.5 M or NDSB-201(2) 1 M/NDSB-256(1) 0.5 M or NDSB-256(2) 1 M.
f 0:1 m
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g EDTA 1 mM; metals: CaCl2, MgCl2, MnCl2, and ZnCl2: 0.25 mM e
xample,  nearly  all  of  the  wells  containing  -cyclodextrin
ave  an  intense  light-blue  color,  greatly  increasing
bsorbance.
The  antibody  recognition  levels  of  soluble  protein  were
nalyzed  with  a  high-throughput  dot  blot  screening  (Fig.  2b).
 simple  visual  analysis  revealed  dots  with  different
ntensities;  however,  in  order  to  achieve  an  accurate  quan-
iﬁcation,  a  computer  program  was  used  to  analyze  the
ensity  of  the  dots  using  a  digitized  image  of  the  membrane
c
d
WM).
one.
ontaining  the  96  spots.  In  addition,  this  program  allowed  us
o  perform  a  detailed  analysis  of  the  effect  of  the  different
enaturing  conditions  on  PA  antibody  binding.
Table  1  and  Fig.  3  show  coefﬁcient  D  values  for  each
ot  in  decreasing  order.  Coefﬁcient  D  values  for  the  best
efolding  conditions  were  ten  times  higher  than  the  value
orresponding  to  the  control  (water,  D  =  119),  allowing  good
iscrimination  between  the  different  conditions  analyzed.
hen  coefﬁcient  D  values  were  compared  with  soluble
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oFigure  2  High-throughput  screening  for  PA  refolding  conditio
dot blot  assay.  The  buffer  and  additives  corresponding  to  each  
protein  concentrations  determined  by  Bradford,  a  good
correlation  was  observed  (Table  1  and  Fig.  4),  except  for
nearly  all  (8/10)  the  wells  containing  -cyclodextrin  due  to
the  intense  blue  color  developed  that  gave  high  absorbance
readings,  as  previously  mentioned.  When  these  eight  wells
were  excluded,  the  highest  coefﬁcient  D  corresponded  to
samples  with  high  soluble  protein  concentrations.  The  two
exceptions  to  beta-cyclodextrin  interference  were  C12  and
D12,  in  which  the  refolding  buffer  was  CHES  pH  9.0.
Statistical  analysis  of  antibody  recognition  of  PAConsidering  a  coefﬁcient  D  cut-off  of  900  to  deﬁne  the
strongest  signals,  no  obvious  combination  of  buffers  and
refolding  additives  stands  out  as  the  best  (Table  1).  The  two
highest  D  values  were  obtained  in  wells  containing  HEPES
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Figure  3  Composite  image  of  the  dots,  showing  Coefﬁcient  D  val
the order  by  decreasing  coefﬁcient  D  values.  Letters  and  number
corresponding to  the  multiwell  plate  and  the  dot  blot  assay  shown  in)  Soluble  protein  concentration  Bradford  assay.  (b)  Soluble  PA
in  the  96-well  plate  are  shown  in  Table  1.
H  7.5  and  CHES  pH  9.0  buffers;  however,  the  remaining
onditions  in  the  wells  above  the  900  cut-off  value  included
ither  TAPS  pH  8.5  or  EPPS  pH  8.0,  and  only  one  contained
OPS  pH  7.0.  When  the  coefﬁcient  D  of  all  conditions  was
lotted  against  the  different  buffers,  a  great  dispersion  was
bserved  for  all  of  them  (Fig.  5),  although  buffer  TAPS  pH
.5  had  the  best  overall  performance,  with  80  %  of  the  wells
hat  contained  it  (15/19)  showing  high  antibody  recognition
coefﬁcient  D  >  760).
When  the  coefﬁcient  D  corresponding  to  the  wells  con-
aining  each  of  the  different  additives  were  compared,  the
nly  one  that  appeared  to  yield  consistently  good  results
as  l-arginine,  as  all  (9/9)  wells  containing  this  additive
ad  values  above  700,  three  of  which  were  higher  than  900
Fig.  5).  Moreover,  in  one  of  the  wells  with  the  highest  coef-
cient  D,  l-arginine  was  the  only  component  present  apart
7 8 9 10 11 12
ues  above  each  dot  while  the  number  at  the  bottom  indicates
s  on  the  top  and  left  margins  indicate  original  dot  location,
 Fig.  2.
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Figure  4  Correlation  between  antibody  recognition  (repre-
sented by  coefﬁcient  D)  and  soluble  protein  concentration
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adetermined  by  Bradford),  for  all  conditions  tested.  Values  lack-
ng correlation,  all  of  them  corresponding  to  wells  containing
-cyclodextrin  (8/10),  are  circled.
rom  the  buffer.  Arginine  is  known  to  improve  protein  solu-
ility  and  inhibit  aggregation  (it  is  a  moderate  chaotrope),
lthough  the  molecular  mechanisms  behind  this  effect  are
till  unclear39.  The  high  signals  obtained  with  l-arginine
gree  with  previously  reported  results5,39,40 indicating  that  it
egularly  allows  efﬁcient  renaturation,  making  l-arginine  an
dditive  of  choice  for  routine  antigenic  recombinant  protein
efolding  protocols.
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igure  5  Coefﬁcient  D  values  corresponding  to  each  refolding  add
 dashed  line,  as  well  as  the  value  for  the  control  well  (containing
dditives were  plotted  together:  NDSB-256,  NDSB-201,  salts,  and  gluM.E.  Pavan  et  al.
All  wells  (10/10)  containing  -cyclodextrin  had  low  coef-
cient  D  values,  with  no  wells  above  765  (Fig.  5).  This  result
ndicated  that  -cyclodextrin  was  not  efﬁcient  to  increase
A  antibody  recognition,  although  it  has  been  reported  to
e  effective  in  the  refolding  of  some  proteins  under  other
onditions2,24,41.  Cyclodextrins  are  known  to  inhibit  protein
ggregation  during  the  refolding  process,  as  they  can  bind  to
ydrophobic  protein  surfaces  increasing  folding  yields39.  As
ur  refolding  efﬁciency  evaluation  was  based  on  the  capa-
ility  of  PA  to  be  recognized  by  antibodies,  we  cannot  rule
ut  that  -cyclodextrin  affects  antibody  binding  in  a  way  not
elated  to  protein  folding,  such  as  hindering  the  accessibility
f  the  antibodies  to  PA  epitopes.  Although  a  great  dispersion
as  observed  for  the  rest  of  the  additives,  almost  all  wells
82  %)  with  coefﬁcient  D  above  900  contained  non-detergent
ulfobetaines  (Table  1).  Two  different  variants,  NDSB-256
nd  NDSB-201,  were  analyzed  at  two  different  concentra-
ions.  One-way  analysis  of  variance  indicated  that  NDSB-256
as  a  statistically  signiﬁcant  (p  =  0.0016)  beneﬁcial  effect  on
A  refolding  only  when  used  at  1  M.  No  signiﬁcant  correla-
ions  were  observed  for  NDSB-201,  although  previous  reports
ave  indicated  that  1  M  NDSB-201  reduced  the  aggregation
f  unfolded  or  partially  unfolded  proteins8,11.
Wells  containing  sorbitol,  trehalose  or  metals  also
howed  great  dispersion,  but  none  had  coefﬁcient  D  values
ver  900.  A  similar  trend  was  observed  for  PEG3350,  with
nly  one  well  above  the  cut-off  value.  Polyethylene  glycol
PEG),  sorbitol  and  trehalose  have  been  proposed  to  act  as
tabilizers  of  protein  structures39.
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itive  and  buffer  system.  The  cut-off  value  of  900  is  shown  with
 water),  nearly  120.  Different  concentrations  of  the  following
tathione  (reduced  and  oxidized).
CT
A
M
p
2
R
1
1
1
1
1High-throughput  screening  of  protective  antigen  refolding  
No  statistically  signiﬁcant  effects  were  observed  for
the  addition  of  the  commonly  used  reduced/oxidized  glu-
tathione  redox  agent13,33 and  wells  containing  this  additive
could  be  observed  along  the  whole  range,  including  the  high-
est  and  lowest  coefﬁcient  D  values  (Fig.  5).  This  is  probably
due  to  the  lack  of  cysteines  in  PA,  which  could  be  involved
in  the  formation  of  disulﬁde  bridges  in  the  protein.  Wells
containing  TCEP  or  EDTA  did  not  reveal  an  effect  of  these
compounds  on  PA  refolding.
Possible  interactions  between  the  different  buffers  and
components  were  assessed  using  a  two-way  analysis  of  vari-
ance.  Glutathione  was  observed  to  interact  with  CHES  pH
9.0  buffer  (p  =  0.001),  reducing  its  effect.  On  the  other
hand,  although  in  the  presence  of  glutathione  the  wells  con-
taining  EPPS,  HEPES  and  TAPS  buffers  had  slightly  higher  D
values,  these  differences  were  not  statistically  signiﬁcant.
When  the  interaction  between  the  buffers  and  metals  was
analyzed,  metals  were  observed  to  reduce  the  effects  of
EPPS  and  HEPES.  No  signiﬁcant  interactions  were  observed
between  buffers  and  l-arginine,  NDSB  or  other  components
such  as  TCEP,  sorbitol,  trehalose,  PEG3350,  EDTA,  salts  and
-cyclodextrin.
Previous  studies  that  focused  on  the  high-throughput
identiﬁcation  of  optimal  conditions  for  protein  renaturation
have  identiﬁed  different  sets  of  conditions  for  different  pro-
teins,  improving  yields  of  biologically  active  proteins9,36--38.
The  determination  of  correct  folding  in  these  studies  is
generally  based  on  in  vitro  assays  of  biological  activity.  A
very  important  property  for  many  biotechnologically  rele-
vant  proteins  used  in  a  variety  of  applications,  including
healthcare  and  diagnostics,  is  their  ability  to  be  recognized
by  speciﬁc  antibodies.  This  property  is  essential  for  bacte-
rial  antigens  used  in  vaccines  and/or  pathogen  detection,
such  as  PA.  The  results  obtained  in  the  present  work  with
this  protein  demonstrated  that  the  different  combinations
of  buffers  and  additives  used  for  refolding  can  signiﬁcantly
affect  its  ability  to  interact  with  antibodies,  and  identiﬁed
the  conditions  that  resulted  in  a  tenfold  increase  of  its  anti-
body  binding  properties  with  a  high  degree  of  discrimination.
The  statistical  analysis  of  the  interactions  between  differ-
ent  components  allowed  to  determine  the  contribution  of
each  of  them  on  PA  refolding  and  the  identiﬁcation  of  both
cooperative  and  negative  interactions.  The  high-throughput
approach  described  in  this  study  can  be  potentially  useful
for  the  rapid  screening  of  adequate  refolding  conditions  for
other  overexpressed  antigens.
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